Premium
Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma
Author(s) -
Seibel Nita L.,
Krailo Mark,
Chen Zhengjia,
Healey John,
Breitfeld Philip P.,
Drachtman Richard,
Greffe Brian,
Nachman James,
Nadel Helen,
Sato Judith K.,
Meyers Paul A.,
Reaman Gregory H.
Publication year - 2007
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.22553
Subject(s) - topotecan , medicine , carboplatin , osteosarcoma , etoposide , chemotherapy , ifosfamide , toxicity , oncology , surgery , gastroenterology , cisplatin , pathology
BACKGROUND. Patients with metastatic osteosarcoma have a poor prognosis. The objectives of the study were to determine the antitumor activity and toxicity of topotecan (daily ×5) in newly diagnosed patients with metastatic osteosarcoma followed by chemotherapy (ifosfamide, carboplatin, etoposide [ICE], alternating with cisplatin and doxorubicin [CD]). METHODS. Newly diagnosed patients (≤30 years of age) with extensive metastatic disease (primary and ≥5 pulmonary nodules and/or bone metastases) with normal hepatic, renal, and cardiac function were eligible. Patients were eligible to receive further topotecan after standard chemotherapy if they exhibited a response. Twenty‐eight patients were enrolled. Seventeen had metastases to the lung only and 11 had metastases to the bone or multiple sites. Of 28 patients enrolled, 27 could be evaluated for response. A limited dose escalation was incorporated. RESULTS. No responses were seen in the 11 patients treated at 3 mg/m 2 /day. One partial response (PR) and 1 clinical response (CLR) were reported among 15 patients who received topotecan at 3.5 mg/m 2 /day. No dose‐limiting toxicity was observed. Principal nondose‐limiting toxicities were hematologic and gastrointestinal. The 2‐ and 5‐year event‐free survival rates were low, 7% and 4%, respectively, but the 2‐ and 5‐year overall survival rates were 44% and 22%, respectively. CONCLUSIONS. Topotecan at dose of 3.5 mg/m 2 /day can be safely administered upfront to newly diagnosed patients without excessive toxicity. Insufficient activity was seen with topotecan in this schedule to warrant further studies in osteosarcoma. The combination of ICE and CD was tolerable when delivered after initial topotecan therapy. Cancer 2007. © 2007 American Cancer Society.